Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is a biotechnology company on a mission to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company’s technology platform leverages allogeneic T-cell immunotherapy to engineer treatments that are off-the-shelf and ready to use for patients with high unmet medical needs.
Despite its promising technology, Atara Biotherapeutics has earned a consensus recommendation of “Hold” from the nine research firms covering the stock. According to Bloomberg.com, three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, and three have given a buy rating to the company. The average 12-month price target among brokerages that issued reports on the stock in the last year is $19.25.
During its last earnings results on May 8th, Atara Biotherapeutics reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.32). The business had revenue of $1.23 million for the quarter compared to the consensus estimate of $37.67 million. This performance was attributed to negative figures; namely, a negative return on equity of 166.74% and a negative net margin of 373.95%, which has led industry analysts to predict that Atara Biotherapeutics will likely post -2.42 EPS for the current year.
This news may bring some disappointment for shareholders; however, it is essential to remember that early-stage biotech companies often experience significant ups and downs in their operations as they navigate through various phases of development and clinical trials towards successful launches into commercial markets.
Moreover, this doesn’t mean Atara Biotherapeutics should be dismissed altogether despite its recent lacklustre performance – especially given its impressive work relating to solid tumours and autoimmune diseases.
Overall, Atara Biotherapeutics continues to be a company worth keeping an eye on, as its technology platform holds tremendous potential. In conclusion, investing in Atara Biotherapeutics may be suitable for risk-tolerant investors who are prepared to endure the roller-coaster ride involved with the biotech industry and to wait for their long-term investments’ returns.
Atara Biotherapeutics Inc.: An Overview of Stock Prices and Analyst Reports.
Atara Biotherapeutics Inc., an allogeneic T-cell immunotherapy company, has been the subject of numerous research analyst reports and experienced changes in stock prices. The firm engages in the development of transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It offers off-the-shelf treatments that are specifically designed to meet high unmet medical needs.
As reported on May 30th, 2023, Atara Biotherapeutics opened at $1.77 per share. Its market capitalization is $173.41 million with a P/E ratio of -0.85 and a beta of 0.96. This range is reflective of its 52 week low of $1.75 and a high of $9.34.
The firm’s management team files timely disclosures about events affecting shareholders’ values, including insider sells by key executives like CEO Pascal Touchon who recently sold 29,766 shares for an average price of $2.04 per share for a total transaction amounting to $60,722.64.
Several hedge funds have purchased or reduced their stakes in Atara Biotherapeutics recently–including the Royal Bank of Canada which lifted its stake by 8.4% during the first quarter–owning already about 25,962 shares valued at $241,000 before acquiring another 2,017 additional shares during the last quarter.
Overall, Atara Biotherapeutics has received mixed investment ratings from various analysts recently: EF Hutton Acquisition Co maintained a “buy” rating while giving shares a target price recommendation of $25; HC Wainwright cut their target price from $29 down to $27; Mizuho restated their “buy” rating but suggested a higher target price at $31.
Investors interested in Atara Biotherapeutics must remain attentive to these developments as they can have significant impacts on both short-term and long-term profitability.
Discussion about this post